Page 67 - Read Online

Page 16 of 16 Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06

176. Luessi F, Engel S, Spreer A, Bittner S, Zipp F. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol
Neuroimmunol Neuroinflamm 2018;5:e481.
177. Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl
fumarate. Neurol Neuroimmunol Neuroinflamm 2016;3:e274.
178. Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment.
Neurology 2019;92:151.
179. Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, et al. Natalizumab-PML survivors with subsequent MS treatment: clinico-
radiologic outcome. Neurol Neuroimmunol Neuroinflamm 2017;4:e346.
180. Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, et al. Natalizumab-induced POU2AF1/Spi-B upregulation: a possible route
for PML development. Neurol Neuroimmunol Neuroinflamm 2016;3:e223.
181. Major EO, Nath A. A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol
Neuroinflamm 2016;3:e235.
182. Bsteh G, Auer M, Iglseder S, Walchhofer LM, Langenscheidt D, et al. Severe early natalizumab-associated PML in MS: Effective
control of PML-IRIS with maraviroc. Neurol Neuroimmunol Neuroinflamm 2017;4:e323.
183. Hodecker SC, Stürner KH, Becker V, Elias-Hamp B, Holst B, et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-
treated patients with MS. Neurol Neuroimmunol Neuroinflamm 2017;4:e325.
184. Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and
lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-7.
185. Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, et al. Efficacy and safety of rituximab in neuromyelitis optica: review
of evidence. J Res Med Sci 2017;22:18.
186. Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, et al. Safety and clinical outcomes of rituximab treatment in patients with
multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J Neuroimmune Pharmacol 2016;11:1-8.
187. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review
and meta-analysis. JAMA Neurol 2016;73:1342-8.
188. Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, et al. Rituximab-induced hypogammaglobulinemia in patients with
neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2018;5:e498.
189. Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol
Neuroimmunol Neuroinflamm 2018;5:e463.
190. Kowarik MC, Hoshi M, Hemmer B, Berthele A. Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. Neurol
Neuroimmunol Neuroinflamm 2016;3:e208.
191. Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol
Neuroimmunol Neuroinflamm 2017;4:e363.
192. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case
series. J Neurol 2016;263:25-9.
193. Trebst C, Jarius S, Berthele A, Paul F, Schippling S. Update on the diagnosis and treatment of neuromyelitis optica: recommendations
of the neuromyelitis optica study group (NEMOS). J Neurol 2014;261:1-16.
194. Popiel M, Psujek M, Bartosik-Psujek H. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during
treatment with dimethyl fumarate. Mult Scler Relat Disord 2018;26:204-6.
195. Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy
and predictors of response. J Neurol Neurosurg Psychiatry 2017;88:639-47.
196. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, et al. Efficacy of glatiramer acetate in neuromyelitis optica
spectrum disorder: a multicenter retrospective study. J Neurol 2016;263:575-82.
197. Jarius S, Ruprecht K, Kleiter, Borisow N, Asgari N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients.
Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J
Neuroinflammation 2016;13:280.
198. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK
study. Brain 2017;140:3128-38.
199. Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in
multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008;266:25-30.
200. Brochet B, Deloire MS, Perez P, Loock T, Baschet L, et al. Double-blind controlled randomized trial of cyclophosphamide versus
methylprednisolone in secondary progressive multiple sclerosis. PLoS One 2017;12:e0168834.
201. Jacques F, Gaboury I, Christie S, Grand’maison F. Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study. Mult
Scler Int 2012;2012:935921.
202. Paul F, Murphy O, Pardo S, Levy M. Investigational drugs in development to prevent neuromyelitis optica relapses. Expert Opin
Investig Drugs 2018;27:265-71.